CN102743370A - 双醋瑞因的新用途 - Google Patents
双醋瑞因的新用途 Download PDFInfo
- Publication number
- CN102743370A CN102743370A CN2012102134603A CN201210213460A CN102743370A CN 102743370 A CN102743370 A CN 102743370A CN 2012102134603 A CN2012102134603 A CN 2012102134603A CN 201210213460 A CN201210213460 A CN 201210213460A CN 102743370 A CN102743370 A CN 102743370A
- Authority
- CN
- China
- Prior art keywords
- diacerein
- body weight
- pharmaceutical composition
- day
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004590 diacerein Drugs 0.000 title claims abstract description 43
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 210000002966 serum Anatomy 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 18
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 48
- 230000037396 body weight Effects 0.000 claims description 38
- 229960003624 creatine Drugs 0.000 claims description 24
- 239000006046 creatine Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 10
- -1 diacerein ester Chemical class 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 62
- 229940109239 creatinine Drugs 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 17
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 201000006328 Fanconi syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000010981 acute adrenal insufficiency Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000008271 glucosaminides Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 206010020917 hypervitaminosis D Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210213460 CN102743370B (zh) | 2011-06-27 | 2012-06-25 | 双醋瑞因的用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110173432 | 2011-06-27 | ||
CN201110173432.9 | 2011-06-27 | ||
CN 201210213460 CN102743370B (zh) | 2011-06-27 | 2012-06-25 | 双醋瑞因的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102743370A true CN102743370A (zh) | 2012-10-24 |
CN102743370B CN102743370B (zh) | 2013-05-15 |
Family
ID=47024105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210213460 Active CN102743370B (zh) | 2011-06-27 | 2012-06-25 | 双醋瑞因的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102743370B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101015541A (zh) * | 2007-02-25 | 2007-08-15 | 上海慈瑞医药科技有限公司 | 二乙酰大黄酸滴丸及其制备方法 |
US20100104651A1 (en) * | 2008-10-28 | 2010-04-29 | Danchen Gao | Pharmaceutical Compositions Containing Diacerein |
-
2012
- 2012-06-25 CN CN 201210213460 patent/CN102743370B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101015541A (zh) * | 2007-02-25 | 2007-08-15 | 上海慈瑞医药科技有限公司 | 二乙酰大黄酸滴丸及其制备方法 |
US20100104651A1 (en) * | 2008-10-28 | 2010-04-29 | Danchen Gao | Pharmaceutical Compositions Containing Diacerein |
Also Published As
Publication number | Publication date |
---|---|
CN102743370B (zh) | 2013-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7829115B2 (en) | Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof | |
KR101292741B1 (ko) | 유파틸린의 신규 용도 | |
AU2017272098A1 (en) | Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a PHY906 extract, a Scutellaria baicalensis GeorgI (S) extract or a compound from such extracts | |
KR20170082456A (ko) | Iga 신장병증을 치료하기 위한 진세노사이드 m1의 용도 | |
EP3275457B1 (en) | Pharmaceutical composition comprising silybin and pu'er tea essence | |
JP2013071909A (ja) | 脳内過酸化脂質蓄積抑制剤 | |
EP0308157B1 (en) | Therapeutic applications of beta-adrenergic agonists | |
JP7361779B2 (ja) | がんに治療的処置をするためのc-19ステロイドの組み合わせ | |
CN102688493A (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 | |
JP6487531B2 (ja) | 漢方薬毛チコリの脂肪降下有効成分を配合した組成物 | |
CN115554323B (zh) | 中药组合物的制备方法及用途 | |
CN102743370B (zh) | 双醋瑞因的用途 | |
JPS6299323A (ja) | 高脂血症剤 | |
WO2019232783A1 (zh) | 大麻二酚组合物及其用途 | |
WO2006030306A2 (en) | Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder | |
CN110833550B (zh) | 吡唑并嘧啶衍生物在治疗急性胰腺炎致肝损伤的用途 | |
CN116570593B (zh) | 一种防止卵巢早衰的药物及其用途 | |
CN112386600B (zh) | 湖贝甲素在制备预防急性肾损伤药物中的用途 | |
CN111249297B (zh) | 一种地高辛在制备用于治疗高睾酮血症的药物中的应用 | |
CN111603473B (zh) | 一种对神经细胞损伤具有保护作用的组合物及其制剂和用途 | |
US20160143885A1 (en) | Treatment Method for Steroid Responsive Dermatoses | |
JP2005514343A5 (zh) | ||
US20100303855A1 (en) | Method of reducing adverse effects of therapeutic agents for dyslipidemia | |
WO2018133104A1 (zh) | 地榆皂苷II羟丙基β-环糊精包合物及其制备方法和用途 | |
WO2018133105A1 (zh) | 地榆皂苷元羟丙基β-环糊精包合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG ZHONGYI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG ZIHOU Effective date: 20140214 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100050 XICHENG, BEIJING TO: 323000 LISHUI, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140214 Address after: No. 279 road 323000 Zhejiang Green Valley City of Lishui province Shuige Industrial Zone Patentee after: ZHEJIANG ZHONGYI PHARMACEUTICAL Co.,Ltd. Address before: 100050 Beijing city Xicheng District South Road No. 2 Building 3 No. 603 9 Patentee before: Wang Zihou |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 279 road 323000 Zhejiang Green Valley City of Lishui province Shuige Industrial Zone Patentee after: Zhejiang Zhongyi Pharmaceutical Co.,Ltd. Address before: No. 279 road 323000 Zhejiang Green Valley City of Lishui province Shuige Industrial Zone Patentee before: ZHEJIANG ZHONGYI PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20151106 Address after: 321000 Zhejiang province Jinhua Bada big industrial zone Mount Huangshan Road No. 328 Patentee after: Zhejiang public health pharmaceutical Co.,Ltd. Address before: No. 279 road 323000 Zhejiang Green Valley City of Lishui province Shuige Industrial Zone Patentee before: Zhejiang Zhongyi Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220930 Address after: 3-801, Area A, Tianzheng Tianyuxi'an Garden, No. 9, Yushu Road, Jiangning District, Nanjing, Jiangsu 211100 Patentee after: Chen Shuqing Address before: 321000 no.328, Bada Road, Dahuangshan Industrial Zone, Jinhua City, Zhejiang Province Patentee before: Zhejiang public health pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |